Literature DB >> 14605498

Reversible posterior leukoencephalopathy syndrome in a child with cerebral X-linked adrenoleukodystrophy treated with cyclosporine after bone marrow transplantation.

A K J Chan1, R Bhargava, S Desai, A Joffe.   

Abstract

Reversible posterior leukoencephalopathy syndrome (RPLS) was described by Hinchey and colleagues in 1996. The disorder occurs predominantly in patients with acute hypertension and/or on pharmacological immunosuppression. We report a 6-year-old male with cerebral X-linked adrenoleukodystrophy who received an HLA-matched unrelated bone marrow transplant (BMT). Cyclosporine was used as graft-versus-host disease prophylaxis. At 55 days post-BMT, his cyclosporine concentrations were high for several days and the concentration was still high on day 70 (353 microg/L). He presented 83 days post-BMT with new onset of headache, lethargy, acute visual loss and focal seizures. He was not hypertensive. MRI of the head revealed signal changes that now extended more peripherally into the subcortical and cortical regions of the occipital and temporal lobes. The patient's cyclosporine was stopped for 5 days. The patient's vision returned to normal and his headaches and lethargy resolved with no further seizures 3 weeks later. Follow-up MRI of the head 2 months later showed almost complete resolution of the cortical signal abnormalities. It is important to consider RPLS in patients with cerebral adrenoleukodystrophy who present with acute neurological deterioration. Attention to the pattern of white matter and the presence of cortical grey matter involvement on neuroimaging is important for the diagnosis. When appropriate management is initiated, that is controlling hypertension when present and discontinuing or reducing the dose of offending immunosuppressive agents, the acute neurological symptoms will usually resolve.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14605498     DOI: 10.1023/a:1025943829843

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  8 in total

Review 1.  Reversible posterior leukoencephalopathy syndrome. Is it reversible and thus benign?

Authors:  T Yamamoto
Journal:  Intern Med       Date:  1999-01       Impact factor: 1.271

Review 2.  Cyclosporine neurotoxicity: a review.

Authors:  J M Gijtenbeek; M J van den Bent; C J Vecht
Journal:  J Neurol       Date:  1999-05       Impact factor: 4.849

3.  Posterior leukoencephalopathy syndrome may not be reversible.

Authors:  N L Antunes; T N Small; D George; F Boulad; E Lis
Journal:  Pediatr Neurol       Date:  1999-03       Impact factor: 3.372

4.  Pre-eclampsia: more than pregnancy-induced hypertension.

Authors:  J M Roberts; C W Redman
Journal:  Lancet       Date:  1993-06-05       Impact factor: 79.321

5.  Cyclosporine-related reversible posterior leukoencephalopathy: MRI.

Authors:  J M Jarosz; D C Howlett; T C Cox; J B Bingham
Journal:  Neuroradiology       Date:  1997-10       Impact factor: 2.804

Review 6.  Posterior leukoencephalopathy syndrome.

Authors:  R K Garg
Journal:  Postgrad Med J       Date:  2001-01       Impact factor: 2.401

7.  The blood brain barrier in human leukodystrophies and allied diseases. Ultrastructural and morphometric studies on the capillaries in brain biopsies.

Authors:  A Kondo; K Suzuki
Journal:  Clin Neuropathol       Date:  1993 May-Jun       Impact factor: 1.368

8.  A reversible posterior leukoencephalopathy syndrome.

Authors:  J Hinchey; C Chaves; B Appignani; J Breen; L Pao; A Wang; M S Pessin; C Lamy; J L Mas; L R Caplan
Journal:  N Engl J Med       Date:  1996-02-22       Impact factor: 91.245

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.